Aptus Endosystems has announced the appointment of James Reinstein as president and CEO, effective 27 February 2012. Reinstein joins Aptus from Cyberonics where he held the position of senior vice president and chief commercial officer. Prior to joining Cyberonics he held executive positions in sales, marketing and senior management in the United States, Europe, Latin America and Asia with Boston Scientific.
Jeff Elkins, the current president and CEO will remain in the company as senior vice president and chief operating officer. Elkins will continue to be a member of the board of directors. Reinstein has also been appointed to Aptus’ board of directors.
Reinstein has a long and successful track record of growing revenues and profits, building effective global teams and introducing new products for market leadership. He led the commercial turnaround at Cyberonics by growing revenues from approximately US$100 million in 2008 to well over US$210 million in this fiscal year. As the general manager of the Epilepsy franchise at Cyberonics, Reinstein led the development of the company’s strategic direction which lays the path for Cyberonics to continue its growth trajectory for many years to come.
“James is a proven leader with the right combination of sales, marketing and operational experience to lead Aptus,” said Alan Kaganov, chairman of the board. “We are pleased to have someone of James’ caliber join Aptus at this important stage of our company history, when Aptus is introducing HeliFX, the innovative endoanchoring technology to the US market.”
“I look forward to working with James on the next phase of our evolution as he understands the opportunity this technology can offer patients who may not have other options. Given our respective backgrounds, he and I will create an ideal partnership to lead the company to great heights of success,” said Elkins.
“I am extremely excited to be joining Aptus. I am confident that my previous professional experience has prepared me well to assume the leadership of this company. The Aptus team has done a tremendous job to be on the precipice of delivering a critical alternative to patients in need of more options for aortic aneurysm disease,” Reinstein said.